The FDA issued a second Complete Response Letter for tabelecleucel, citing concerns over trial design and data interpretability in EBV+ PTLD.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback